CYTEGEN CORP

Shorewood, WI · Founded 2014 · Biotech · Private

Engineered circulating factors derived from exercise-induced endogenous molecules to restore mitochondrial function

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · cytegen.com

Sector: Biotech
Headquarters: Shorewood, WI
Founded: 2014
Latest Form D: $1.1M, Jan 2022
Total capital: $3.1M

Federal grants: $956K; 4 awards · 2017–2020; Rank in peer group#209 of 392
Private capital raised: $2.1M; 2 Form D · last Jan 2022; 57 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 3 pending

Capital timeline

Latest events

Jan 2022Private capital raisedForm D · SEC · 2nd filing$1.1M
Sep 2020Federal grantHealth and Human S · Phase I · Determination of circulation factors that mediate the health benefits of exercise in mitochondrial aging$252K
Aug 2020Federal grantHealth and Human S · Phase I · Determination of circulation factors that mediate the health benefits of exercise in mitochondrial aging$252K
Jun 2018Federal grantHealth and Human S · Phase I · Selection and Development of a Lead Biologic for Treating Mitochondrial Disorders$242K
Apr 2018Private capital raisedForm D · SEC · 1st filing$1M
Sep 2017Federal grantHealth and Human S · Phase I · A Novel Strategy to Identify Substances that Improve Mitochnodrial Fitness$211K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

7months

from CYTEGEN CORP’s first federal award to its first private round.

First federal award · Sep 2017: Health and Human S · $211K
First Form D · Apr 2018: $1M · 1st Form D
Awards before first raise: 1 award

An association in public records, not a cause or a prediction.

Standing among 392 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

GEORGE UGRAS NURAYExecutive Officer, DirectorNamed in SEC Form D filings
MICHAEL GEORGE HARTEDirectorNamed in SEC Form D filings
NURAY GEORGE UGRASExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 3

Nov 17, 2022PendingTreatment of Mitochondrial Deficits and Age-Related Diseases Using Blood ProductsUSPTOApplication 17763005
PendingTreatment Of Mitochondrial Deficits And Age-related Diseases Using Blood ProductsUSPTOApplication PCTUS2020052518
PendingTreatment Of Mitochondrial Deficits And Age-related Diseases Using Blood ProductsUSPTOApplication 62905817

Scribe Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
GENEVENTIV THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
BIOSYMETRICS, INC.Similar federal contract value in Biotech · null in contracts
BYOMASS, INC.Similar federal contract value in Biotech · null in contracts
G1 THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
EXAI BIO, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.